Clinical Trials on C. Difficile

Total 3313 results

Vedanta Biosciences, Inc.

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection (RESTORATiVE303)

Clostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection

United States
University of Wisconsin, Madison
Mayo Clinic; Medical College of Wisconsin; Agency for Healthcare Research and... and other collaborators

Completed

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | CDI | C.Difficile Diarrhea | C. Diff Colitis | C.Difficile Colitis

United States
Danisco
University of Turku

Completed

Probiotic Intervention With Elderly Subjects

Intestinal C. Difficile

Finland
Brigham and Women's Hospital
Centers for Disease Control and Prevention; Harvard Pilgrim Health Care Institute and other collaborators

Recruiting

Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile

C. Difficile

United States
State University of New York at Buffalo

Withdrawn

Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy (c diff)

C. Difficile Infection

United States
Deinove

Recruiting

An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection

Clostridium Difficile (C. Difficile)

United States, Canada
Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
Providence Holy Cross Medical Center

Unknown

Reduction of C-Difficile Infection Using Stool Transplant (FMT)

C-difficile

United States
University of Wisconsin, Madison
Agency for Healthcare Research and Quality (AHRQ)

Enrolling by invitation

FQ Restriction for the Prevention of CDI (FIRST)

Clostridium Difficile Infection | Clostridium Difficile | C Difficile Colitis

United States
The University of Texas Health Science Center,...
Kelsey Research Foundation; Roderick MacDonald Research Fund at Baylor St.... and other collaborators

Completed

Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route

C. Difficile

United States
University of Zurich
Luzerner Kantonsspital; Kantonsspital Winterthur KSW; Cantonal Hosptal, Baselland and other collaborators

Recruiting

Support of Colonization Resistance of the Gut Microbiota With the Synbiotic Food Supplement Nagasin®

C. Difficile Enteritis

Switzerland
Memorial Sloan Kettering Cancer Center

Completed

Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection

Cancer | C. Difficile Infection

United States
The University of Texas Health Science Center,...

Terminated

Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)

Recurrent C. Difficile Infection

United States
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
The University of Texas Health Science Center,...

Completed

Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea

Recurrent C. Difficile Associated Diarrhea

United States
Duke University

Completed

Impact of Oral Antibiotic Treatment on C. Difficile (C-Diff)

Diarrhea | Enterocolitis | C. Difficile

United States
Baylor College of Medicine
Michael E. DeBakey VA Medical Center

Enrolling by invitation

Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea

Active C. Difficile Colitis

United States
Hospital General Universitario Gregorio Marañon

Unknown

Clostridium Difficile Infection (CDI) in Hematologic Patients.

C.Difficile Diarrhea

Spain
University of Wisconsin, Madison
Agency for Healthcare Research and Quality (AHRQ)

Completed

The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation (GRAFT)

Clostridium Difficile Infection | CDI | C.Difficile Diarrhea

United States
Vedanta Biosciences, Inc.

Completed

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection (CONSORTIUM)

Clostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection Recurrence

United States, Canada
University of Virginia
Imperial College London

Recruiting

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) (ACT)

Clostridium Difficile Infection | Clostridium Difficile Diarrhea | Clostridioides Difficile Infection | Clostridia Difficile Colitis

United States
Pfizer

Recruiting

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons. It Will Be Given Twice Over a Period of Time to Healthy Adults

Clostridoides Difficile Associated Disease

United States
Hamilton Health Sciences Corporation

Recruiting

Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients (Decency-RCT)

Clostridium Difficile Diarrhea | Clostridium Difficile Colonization

Canada
University of Arkansas

Withdrawn

UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients

Candidemia | Aspergillosis | C. Difficile

United States
Mikrobiomik Healthcare Company S.L.

Completed

Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin

Recurrent Clostridium Difficile Infection | Primary Clostridium Difficile Infection

Spain
Lazarski University

Completed

Duble Lumen Intubation

Intubation; Difficult or Failed | Difficult Airway | Intubation;Difficult

Poland
University of Pennsylvania

Terminated

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

Severe Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile Infection

United States
University Health Network, Toronto

Terminated

Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin

Recurrent Clostridium Difficile Infection | Laboratory Confirmed Clostridium Difficile Infection

Canada
Pfizer

Completed

Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

Clostridium Difficile Associated Disease

United States
MJM Bonten
Universiteit Antwerpen; Universitätsklinikum Köln; Da Volterra

Completed

AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment (ANTICIPATE)

Clostridium Difficile

Germany, Spain, France, Greece, Netherlands, Romania
Astellas Pharma Europe Ltd.
Cubist Pharmaceuticals LLC

Terminated

A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System (FREEDOM)

Clostridium Difficile

Spain, France, Germany, Greece, Denmark, Austria, Poland
Chinese University of Hong Kong

Unknown

Clostridium Difficile Virulence Mechanism Study (CDVM Study) (CDVM)

Clostridium Difficile Infection | Clostridium Difficile

Hong Kong
Medical University of Silesia

Unknown

Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain

Clostridium Difficile
Hvidovre University Hospital

Unknown

Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections

Clostridium Difficile

Denmark
Pfizer

Completed

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Clostridium Difficile Associated Disease

United States
Microbiome Health Research Institute
Brown University; Tufts Medical Center; Indiana University; Edward Hospital

Terminated

Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection (STOOL)

Clostridium Difficile

United States
Seres Therapeutics, Inc.
Syneos Health

Completed

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) (ECOSPOR)

Clostridium Difficile

United States
Gabriella C. van Zanten

Completed

Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly

Probiotics | Elderly | Gut Microbiota | Clostridium Difficile | Fecal Metabolome

Denmark
University of Alberta
University of British Columbia; McGill University; University of Calgary

Completed

Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection

Clostridium Difficile Diarrhea | Clostridia Difficile Colitis

Canada
Jewish General Hospital

Terminated

Loop Ileostomy With Colonic Lavage for Fulminant Clostridium Difficile Colitis

Fulminant Clostridium Difficile Colitis

Canada
Assistance Publique - Hôpitaux de Paris

Recruiting

Safety Registry of a Fecal Microbiota Transplant Cohort (COSMIC-FMT)

Clostridium Difficile Infections

France
University of North Carolina, Chapel Hill
North Carolina Translational and Clinical Sciences Institute; North Carolina...

Completed

Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics (FMT)

Clostridium Difficile

United States
Pfizer

Completed

A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

Clostridium Difficile Associated Disease

United States
Pfizer

Completed

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

Clostridium Difficile Associated Disease

United States
University of Alberta

Terminated

Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection

Clostridium Difficile

Canada
McMaster University
St. Joseph's Healthcare Hamilton

Terminated

A Prospective Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection

Clostridium Difficile

Canada
Astellas Pharma Europe Ltd.
Merck Sharp & Dohme LLC

Completed

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population (EXTEND)

Clostridium Difficile

Greece, Spain, Russian Federation, Denmark, Austria, Belgium, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland, Turkey, United Kingdom
University Hospital Tuebingen

Unknown

Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis (TOCSIN)

Clostridium Difficile Infection | Clostridium Difficile

Germany
Derince Training and Research Hospital

Completed

Evaluation of Intubation Rescue Techniques on Management of Difficult Airway

Difficult Intubation | Difficult Airway

Turkey
Alexandria University

Active, not recruiting

Effectiveness of C-MAC Video-stylet Versus C-MAC D- Blade Video-laryngoscope for Tracheal Intubation

Difficult Intubation | Difficult Mask Ventilation

Egypt

Clinical Trials on C. Difficile

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations